Successful Bosentan and Nonnucleoside Reverse Transcriptase Inhibitor‐Based Therapy in a Patient with Acquired Immunodeficiency Syndrome and Pulmonary Arterial Hypertension

Hardy, Hélène; Backman, Elke; Farber, Harrison W.

doi:10.1592/phco.30.4.422

Cited by 6 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An interaction between PAH specific therapy and HIV drugs was described by Hardy et al . about a 51‐year‐old female with AIDS and HIV‐PAH. She was treated with bosentan while taking a nevirapine (a nonnucleoside reverse‐transcriptase inhibitor NNRTI)‐based antiretroviral regimen.…”

Section: Drugs Interactionmentioning

confidence: 99%

HIV‐associated pulmonary arterial hypertension: from bedside to the future

Correale

Palmiotti

Storto

et al. 2015

Eur J Clin Investigation

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a life-threatening complication of HIV infection. The prevalence of HIVassociated PAH (HIV-PAH) seems not to be changed over time, regardless of the introduction of highly active antiretroviral therapy (HAART). In comparison with the incidence of idiopathic PAH in the general population (1-2 per million), HIV-infected patients have a 2500-fold increased risk of developing PAH. HIV-PAH treatment is similar to that for all PAH conditions and includes lifestyle changes, general treatments and specific treatments.

show abstract

Section: Drugs Interactionmentioning

confidence: 99%

HIV‐associated pulmonary arterial hypertension: from bedside to the future

Correale

Palmiotti

Storto

et al. 2015

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…In patients with PAH, bosentan, a combined ET A and ET B receptor agonist, decreases pulmonary vascular resistance, and pulmonary pressures, increases cardiac output, and improves exercise tolerance [142]. Significant benefits of bosentan treatment have been demonstrated in children with PAH [143], in PAH associated with human immunodeficiency virus [144], and in patients with portopulmonary hypertension [145]. However, bosentan can produce hepatotoxicity and liver enzymes must be monitored during its use.…”

Section: Sgc Activatorsmentioning

confidence: 99%

Reactive oxygen and nitrogen species in pulmonary hypertension

Tabima

Frizzell

Gladwin

2012

Free Radical Biology and Medicine

166

143

View full text Add to dashboard Cite

Pulmonary vascular disease can be defined as either a disease affecting the pulmonary capillaries and pulmonary arterioles, termed pulmonary arterial hypertension, or as a disease affecting the left ventricle, called pulmonary venous hypertension. Pulmonary arterial hypertension (PAH) is a disorder of the pulmonary circulation characterized by endothelial dysfunction, as well as intimal and smooth muscle proliferation. Progressive increases in pulmonary vascular resistance and pressure impair the performance of the right ventricle, resulting in declining cardiac output, reduced exercise capacity, right heart failure, and ultimately death. While the primary and heritable forms of the disease are thought to affect over 5,000 patients in the U.S., the disease can occur secondary to congenital heart disease, most advanced lung diseases, and many systemic diseases. Multiple studies implicate oxidative stress in the development of PAH. Further, this oxidative stress has been shown to be associated with alterations in reactive oxygen species (ROS), reactive nitrogen species (RNS) and nitric oxide (NO) signaling pathways, whereby bioavailable NO is decreased and ROS and RNS production are increased. Many canonical ROS and NO signaling pathways are simultaneously disrupted in PAH, with increased expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and xanthine oxidoreductase, uncoupling of endothelial NO synthase (eNOS), and reduction in mitochondrial number, as well as impaired mitochondrial function. Upstream dysregulation of ROS/NO redox homeostasis impairs vascular tone and contributes to the pathological activation of anti-apoptotic and mitogenic pathways, leading to cell proliferation and obliteration of the vasculature. This manuscript will review the available data regarding the role of oxidative and nitrosative stress and endothelial dysfunction in the pathophysiology of pulmonary hypertension, and provide a description of targeted therapies for this disease.

show abstract

“…Bosentan interacted with warfarin with CYP2C9 and CYP3A4 as connective nodes. Coadministration of bosentan 500 mg twice daily for 6 days decreases the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29% and 38%, respectively 39 The networks will not only show which proteins are more important for DDIs but also provide some mechanistic illuminations. The mechanisms of DDIs may be classified into pharmacokinetic and pharmacodynamic 2 .…”

Section: Resultsmentioning

confidence: 99%

A novel algorithm for analyzing drug-drug interactions from MEDLINE literature

Yin

Shen

Pietsch

et al. 2015

Sci Rep

View full text Add to dashboard Cite

Drug–drug interaction (DDI) is becoming a serious clinical safety issue as the use of multiple medications becomes more common. Searching the MEDLINE database for journal articles related to DDI produces over 330,000 results. It is impossible to read and summarize these references manually. As the volume of biomedical reference in the MEDLINE database continues to expand at a rapid pace, automatic identification of DDIs from literature is becoming increasingly important. In this article, we present a random-sampling-based statistical algorithm to identify possible DDIs and the underlying mechanism from the substances field of MEDLINE records. The substances terms are essentially carriers of compound (including protein) information in a MEDLINE record. Four case studies on warfarin, ibuprofen, furosemide and sertraline implied that our method was able to rank possible DDIs with high accuracy (90.0% for warfarin, 83.3% for ibuprofen, 70.0% for furosemide and 100% for sertraline in the top 10% of a list of compounds ranked by p-value). A social network analysis of substance terms was also performed to construct networks between proteins and drug pairs to elucidate how the two drugs could interact.

show abstract

Successful Bosentan and Nonnucleoside Reverse Transcriptase Inhibitor‐Based Therapy in a Patient with Acquired Immunodeficiency Syndrome and Pulmonary Arterial Hypertension

Cited by 6 publications

References 17 publications

HIV‐associated pulmonary arterial hypertension: from bedside to the future

HIV‐associated pulmonary arterial hypertension: from bedside to the future

Reactive oxygen and nitrogen species in pulmonary hypertension

A novel algorithm for analyzing drug-drug interactions from MEDLINE literature

Contact Info

Product

Resources

About